No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- Sampath Kumar PallerlamudiDesignation :- Company Secretary and Compliance Officer

Gland Pharma Ltd.

08 Apr 2021

1886.00

0.49%

Company Update

Gland Pharma Ltd - 543245 - Format of Initial Disclosure to be made by an entity …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayGland Pharma Ltd 2CINU24239TG1978PLC002276 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 4.07 4Highest Credit Rating during the previous FY NA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Sampath Kumar Pallerlamudi Designation: Company Secretary EmailId: sampath@glandpharma.com Name of the Chief Financial Officer: Ravi Shekhar Mitra Designation: Chief Financial Officer EmailId: Ravi.Mitra@glandpharma.com Date: 08/04/2021 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Gland Pharma Ltd.

05 Apr 2021

1886.00

0.49%

Company Update

Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Copy of newspaper publication on the Board meeting notice

pdf

Gland Pharma Ltd.

03 Apr 2021, 08:42PM

1886.00

0.49%

Board Meeting

Gland Pharma Ltd - 543245 - Board Meeting Intimation for To Consider And Approve The Financial …

BSE India

Gland Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 17/05/2021 ,inter alia, to consider and approve the Audited financial results of the Company for the quarter and financial year ended March 31, 2021.

pdf

Gland Pharma Ltd.

31 Mar 2021

1886.00

0.49%

SAST

Gland Pharma Ltd - 543245 - Closure of Trading Window

BSE India

Closure of Trading window from Thursday, April 1, 2021 till 48 hours after the declaration of the Audited financial results of the Company for the quarter and financial year ended March 31, 2021.

pdf